| O'Hara MW, Pearlstein T, Stuart S, Long JD, Mills JA, Zlotnick C. "A placebo controlled treatment trial of sertraline and interpersonal psychotherapy for postpartum depression." Journal of affective disorders, vol. 245, 2018, pp. 524-532. |
| Ismaili, Elgerta, Walsh, Sally, O’Brien, Patrick Michael Shaughn, Bäckström, Torbjorn, Brown, Candace, Dennerstein, Lorraine, Eriksson, Elias, Freeman, Ellen W., Ismail, Khaled M. K., Panay, Nicholas, Pearlstein, Teri, Rapkin, Andrea, Steiner, Meir, Studd, John, Sundström-Paromma, Inger, Endicott, Jean, Epperson, C. Neill, Halbreich, Uriel, Reid, Robert, Rubinow, David, Schmidt, Peter, Yonkers, Kimberley. "Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder." Archives of Women's Mental Health, 2016. |
| Sharkey, Katherine M., Iko, Ijeoma N., Machan, Jason T., Thompson-Westra, Johanna, Pearlstein, Teri B. "Infant sleep and feeding patterns are associated with maternal sleep, stress, and depressed mood in women with a history of major depressive disorder (MDD)." Archives of Women's Mental Health, vol. 19, no. 2, 2016, pp. 209-218. |
| Pearlstein, Teri. "Treatment of Premenstrual Dysphoric Disorder: Therapeutic Challenges." Expert Review of Clinical Pharmacology, 2016. |
| Pearlstein T. "Depression during Pregnancy." Best practice & research. Clinical obstetrics & gynaecology, vol. 29, no. 5, 2015, pp. 754-64. |
| Pearlstein, Teri. "Perinatal Mental Health." J. Clin. Psychiatry, 2015, pp. e1041-e1041[book review]. |
| Pistorello, Jacqueline, Hayes, Steven, Costello, Ellen, Simpson, Elizabeth, Begin, Ann, Rosen, Karen, Pearlstein, Teri. "Suppression, Acceptance, and Monitoring of Personally-Relevant Unwanted Thoughts in Women Diagnosed with Borderline Personality Disorder." Journal of Experimental Psychopathology, vol. 6, no. 4, 2015, pp. 411-432. |
| Yonkers KA, Pearlstein TB, Gotman N. "A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome." Journal of Clinical Psychopharmacology, vol. 33, no. 5, 2013, pp. 614-20. |
| Davis K, Pearlstein T, Stuart S, O'Hara M, Zlotnick C. "Analysis of brief screening tools for the detection of postpartum depression: comparisons of the PRAMS 6-item instrument, PHQ-9, and structured interviews." Archives of Women's Mental Health, vol. 16, no. 4, 2013, pp. 271-7. |
| Sharkey KM, Pearlstein TB, Carskadon MA. "Circadian phase shifts and mood across the perinatal period in women with a history of major depressive disorder: a preliminary communication." Journal of affective disorders, vol. 150, no. 3, 2013, pp. 1103-8. |
| Ismail KM, Nevatte T, O'Brien S, Paschetta E, Bäckström T, Dennerstein L, Eriksson E, Freeman EW, Panay N, Pearlstein T, Rapkin A, Steiner M, Studd J, Sundström-Poromaa I. "Clinical subtypes of core premenstrual disorders: a Delphi survey." Archives of Women's Mental Health, vol. 16, no. 3, 2013, pp. 197-201. |
| Buttner MM, Mott SL, Pearlstein T, Stuart S, Zlotnick C, O'Hara MW. "Examination of premenstrual symptoms as a risk factor for depression in postpartum women." Archives of Women's Mental Health, vol. 16, no. 3, 2013, pp. 219-25. |
| Nevatte T, O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman EW, Halbreich U, Ismail K, Panay N, Pearlstein T, Rapkin A, Reid R, Rubinow D, Schmidt P, Steiner M, Studd J, Sundström-Poromaa I, Yonkers K, Consensus Group of the International Society for Premenstrual Disorders. "ISPMD consensus on the management of premenstrual disorders." Archives of Women's Mental Health, vol. 16, no. 4, 2013, pp. 279-91. |
| Pearlstein T. "Use of psychotropic medication during pregnancy and the postpartum period." Women's health (London, England), vol. 9, no. 6, 2013, pp. 605-15. |
| Creech S, Davis K, Howard M, Pearlstein T, Zlotnick C. "Psychological/verbal abuse and utilization of mental health care in perinatal women seeking treatment for depression." Archives of Women's Mental Health, vol. 15, no. 5, 2012, pp. 361-5. |
| Pearlstein T. "Psychotropic medications and other non-hormonal treatments for premenstrual disorders." Menopause international, vol. 18, no. 2, 2012, pp. 60-4. |
| Salisbury, Amy L., Wisner, Katherine L., Pearlstein, Teri, Battle, Cynthia L., Stroud, Laura, Lester, Barry M. "Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment." Depression and Anxiety, vol. 28, no. 11, 2011, pp. 1008-1019. |
| O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman E, Halbreich U, Ismail KM, Panay N, Pearlstein T, Rapkin A, Reid R, Schmidt P, Steiner M, Studd J, Yonkers K. "Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus." Archives of Women's Mental Health, vol. 14, no. 1, 2011, pp. 13-21. |
| Pearlstein T. "Premenstrual dysphoric disorder: out of the appendix." Archives of Women's Mental Health, vol. 13, no. 1, 2010, pp. 21-3. |
| Pearlstein T, Howard M, Salisbury A, Zlotnick C. "Postpartum depression." American Journal of Obstetrics and Gynecology, vol. 200, no. 4, 2009, pp. 357-64. |
| Battle, Cynthia L., Zlotnick, Caron, Pearlstein, Teri, Miller, Ivan W., Howard, Margaret, Salisbury, Amy, Stroud, Laura. "Depression and breastfeeding: which postpartum patients take antidepressant medications?." Depression and Anxiety, vol. 25, no. 10, 2008, pp. 888-891. |
| Pearlstein T. "Perinatal depression: treatment options and dilemmas." Journal of psychiatry & neuroscience : JPN, vol. 33, no. 4, 2008, pp. 302-18. |
| Pearlstein T, Steiner M. "Premenstrual dysphoric disorder: burden of illness and treatment update." Journal of psychiatry & neuroscience : JPN, vol. 33, no. 4, 2008, pp. 291-301. |
| Zlotnick C, Miller IW, Pearlstein T, Howard M, Sweeney P. "A preventive intervention for pregnant women on public assistance at risk for postpartum depression." American Journal of Psychiatry, vol. 163, no. 8, 2006, pp. 1443-5. |
| Howard M, Battle CL, Pearlstein T, Rosene-Montella K. "A psychiatric mother-baby day hospital for pregnant and postpartum women." Archives of Women's Mental Health, vol. 9, no. 4, 2006, pp. 213-8. |
| Battle CL, Zlotnick C, Miller IW, Pearlstein T, Howard M. "Clinical characteristics of perinatal psychiatric patients: a chart review study." The Journal of Nervous and Mental Disease, vol. 194, no. 5, 2006, pp. 369-77. |
| Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K. "Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs." Journal of Women's Health, vol. 15, no. 1, 2006, pp. 57-69. |
| Kornstein SG, Pearlstein TB, Fayyad R, Farfel GM, Gillespie JA. "Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies." J. Clin. Psychiatry, vol. 67, no. 10, 2006, pp. 1624-32. |
| Pearlstein TB, Zlotnick C, Battle CL, Stuart S, O'Hara MW, Price AB, Grause MA, Howard M. "Patient choice of treatment for postpartum depression: a pilot study." Archives of Women's Mental Health, vol. 9, no. 6, 2006, pp. 303-8. |
| Pearlstein T. "Will oral contraceptives join SSRIs as a first-line treatment option for women with premenstrual dysphoric disorder?." Women's health (London, England), vol. 2, no. 2, 2006, pp. 183-5. |
| Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. "Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder." Obstetrics and gynecology, vol. 106, no. 3, 2005, pp. 492-501. |
| Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. "Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase." Journal of affective disorders, vol. 85, no. 3, 2005, pp. 317-21. |
| Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. "Pretreatment pattern of symptom expression in premenstrual dysphoric disorder." Journal of affective disorders, vol. 85, no. 3, 2005, pp. 275-82. |
| Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. "Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation." Contraception, vol. 72, no. 6, 2005, pp. 414-21. |
| Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, Pearlstein T. "Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder." J. Clin. Psychiatry, vol. 65, no. 3, 2004, pp. 379-85. |
| Pearlstein T, Spurell E, Hohlstein LA, Gurney V, Read J, Fuchs C, Keller MB. "A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response." Archives of Women's Mental Health, vol. 6, no. 2, 2003, pp. 147-51. |
| Yonkers KA, Pearlstein T, Rosenheck RA. "Premenstrual disorders: bridging research and clinical reality." Archives of Women's Mental Health, vol. 6, no. 4, 2003, pp. 287-92. |
| Pearlstein T, Joliat MJ, Brown EB, Miner CM. "Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment." American Journal of Obstetrics and Gynecology, vol. 188, no. 4, 2003, pp. 887-95. |
| Pearlstein T, Yonkers KA. "Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder." Expert opinion on pharmacotherapy, vol. 3, no. 7, 2002, pp. 979-91. |
| Pearlstein T. "Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?." Drugs, vol. 62, no. 13, 2002, pp. 1869-85. |
| Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J, Maddock R, Hegel MT, Farfel G. "Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study." American Journal of Psychiatry, vol. 158, no. 12, 2001, pp. 1974-81. |
| Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M, PMS/PMDD Research Group. "Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder." Journal of women's health & gender-based medicine, vol. 10, no. 6, 2001, pp. 561-9. |
| Zlotnick C, Johnson SL, Miller IW, Pearlstein T, Howard M. "Postpartum depression in women receiving public assistance: pilot study of an interpersonal-therapy-oriented group intervention." American Journal of Psychiatry, vol. 158, no. 4, 2001, pp. 638-40. |
| Pearlstein T. "Antidepressant treatment of posttraumatic stress disorder." J. Clin. Psychiatry, vol. 61 Suppl 7, 2000, pp. 40-3. |
| Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM. "Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial." JAMA, vol. 283, no. 14, 2000, pp. 1837-44. |
| Pearlstein T, Steiner M. "Non-antidepressant treatment of premenstrual syndrome." J. Clin. Psychiatry, vol. 61 Suppl 12, 2000, pp. 22-7. |
| Steiner M, Pearlstein T. "Premenstrual dysphoria and the serotonin system: pathophysiology and treatment." J. Clin. Psychiatry, vol. 61 Suppl 12, 2000, pp. 17-21. |
| Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, Yonkers KA. "Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo." J. Clin. Psychiatry, vol. 61, no. 2, 2000, pp. 101-9. |
| Zlotnick C, Warshaw M, Shea MT, Allsworth J, Pearlstein T, Keller MB. "Chronicity in posttraumatic stress disorder (PTSD) and predictors of course of comorbid PTSD in patients with anxiety disorders." Journal of Traumatic Stress , vol. 12, no. 1, 1999, pp. 89-100. |
| Endicott J, Amsterdam J, Eriksson E, Frank E, Freeman E, Hirschfeld R, Ling F, Parry B, Pearlstein T, Rosenbaum J, Rubinow D, Schmidt P, Severino S, Steiner M, Stewart DE, Thys-Jacobs S. "Is premenstrual dysphoric disorder a distinct clinical entity?." Journal of women's health & gender-based medicine, vol. 8, no. 5, 1999, pp. 663-79. |
| Pearlstein T, Diaz S, Howard M, Zlotnick C, Jain N. "Dysphoric disorders in women: a case of perinatal depression." Medscape women's health, vol. 3, no. 4, 1998, pp. 1. |
| Pearlstein T, Jain N, Zlotnick C, Howard M, Diaz S. "Interactive case challenge. Dysphoric disorders in women: a case of premenstrual syndrome." Medscape women's health, vol. 3, no. 5, 1998, pp. 2. |
| Pearlstein T, Stone AB. "Premenstrual syndrome." Psychiatric Clinics of North America, vol. 21, no. 3, 1998, pp. 577-90. |
| Simpson EB, Pistorello J, Begin A, Costello E, Levinson J, Mulberry S, Pearlstein T, Rosen K, Stevens M. "Use of dialectical behavior therapy in a partial hospital program for women with borderline personality disorder." PS, vol. 49, no. 5, 1998, pp. 669-73. |
| Fava M, Nierenberg AA, Quitkin FM, Zisook S, Pearlstein T, Stone A, Rosenbaum JF. "A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia." Psychopharmacology bulletin, vol. 33, no. 1, 1997, pp. 101-3. |
| Zlotnick C, Donaldson D, Spirito A, Pearlstein T. "Affect regulation and suicide attempts in adolescent inpatients." Journal of the American Academy of Child & Adolescent Psychiatry, vol. 36, no. 6, 1997, pp. 793-8. |
| Zlotnick C, Shea TM, Rosen K, Simpson E, Mulrenin K, Begin A, Pearlstein T. "An affect-management group for women with posttraumatic stress disorder and histories of childhood sexual abuse." Journal of Traumatic Stress , vol. 10, no. 3, 1997, pp. 425-36. |
| Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA. "Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder." Journal of Clinical Psychopharmacology, vol. 17, no. 4, 1997, pp. 261-6. |
| Pearlstein T, Rosen K, Stone AB. "Mood disorders and menopause." Endocrinology and metabolism clinics of North America, vol. 26, no. 2, 1997, pp. 279-94. |
| Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison W. "Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group." JAMA, vol. 278, no. 12, 1997, pp. 983-8. |
| Shelton RC, Davidson J, Yonkers KA, Koran L, Thase ME, Pearlstein T, Halbreich U. "The undertreatment of dysthymia." J. Clin. Psychiatry, vol. 58, no. 2, 1997, pp. 59-65. |
| Zlotnick C, Shea MT, Recupero P, Bidadi K, Pearlstein T, Brown P. "Trauma, dissociation, impulsivity, and self-mutilation among substance abuse patients." The American journal of orthopsychiatry, vol. 67, no. 4, 1997, pp. 650-4. |
| Zlotnick C, Pearlstein T. "Validation of the structured interview for disorders of extreme stress." Comprehensive Psychiatry, vol. 38, no. 4, 1997, pp. 243-7. |
| Zlotnick C, Shea MT, Pearlstein T, Begin A, Simpson E, Costello E. "Differences in dissociative experiences between survivors of childhood incest and survivors of assault in adulthood." The Journal of Nervous and Mental Disease, vol. 184, no. 1, 1996, pp. 52-4. |
| Yonkers KA, Halbreich U, Freeman E, Brown C, Pearlstein T. "Sertraline in the treatment of premenstrual dysphoric disorder." Psychopharmacology bulletin, vol. 32, no. 1, 1996, pp. 41-6. |
| Zlotnick C, Zakriski AL, Shea MT, Costello E, Begin A, Pearlstein T, Simpson E. "The long-term sequelae of sexual abuse: support for a complex posttraumatic stress disorder." Journal of Traumatic Stress , vol. 9, no. 2, 1996, pp. 195-205. |
| Zlotnick C, Shea MT, Pearlstein T, Simpson E, Costello E, Begin A. "The relationship between dissociative symptoms, alexithymia, impulsivity, sexual abuse, and self-mutilation." Comprehensive Psychiatry, vol. 37, no. 1, 1996, pp. 12-6. |
| Zlotnick C, Hohlstein LA, Shea MT, Pearlstein T, Recupero P, Bidadi K. "The relationship between sexual abuse and eating pathology." The International journal of eating disorders, vol. 20, no. 2, 1996, pp. 129-34. |
| Zlotnick C, Shea MT, Begin A, Pearlstein T, Simpson E, Costello E. "The validation of the Trauma Symptom Checklist-40 (TSC-40) in a sample of inpatients." Child Abuse & Neglect, vol. 20, no. 6, 1996, pp. 503-10. |
| Zlotnick C, Davidson J, Shea MT, Pearlstein T. "Validation of the Davidson Trauma Scale in a sample of survivors of childhood sexual abuse." The Journal of Nervous and Mental Disease, vol. 184, no. 4, 1996, pp. 255-7. |
| Pearlstein TB. "Hormones and depression: what are the facts about premenstrual syndrome, menopause, and hormone replacement therapy?." American Journal of Obstetrics and Gynecology, vol. 173, no. 2, 1995, pp. 646-53. |
| Zlotnick C, Shea MT, Zakriski A, Costello E, Begin A, Pearlstein T, Simpson E. "Stressors and close relationships during childhood and dissociative experiences in survivors of sexual abuse among inpatient psychiatric women." Comprehensive Psychiatry, vol. 36, no. 3, 1995, pp. 207-12. |
| Stone AB, Pearlstein TB. "Evaluation and treatment of changes in mood, sleep, and sexual functioning associated with menopause." Obstetrics and gynecology clinics of North America, vol. 21, no. 2, 1994, pp. 391-403. |
| Pearlstein TB, Stone AB. "Long-term fluoxetine treatment of late luteal phase dysphoric disorder." J. Clin. Psychiatry, vol. 55, no. 8, 1994, pp. 332-5. |
| Zlotnick C, Begin A, Shea MT, Pearlstein T, Simpson E, Costello E. "The relationship between characteristics of sexual abuse and dissociative experiences." Comprehensive Psychiatry, vol. 35, no. 6, 1994, pp. 465-70. |
| Pearlstein T, Rivera-Tovar A, Frank E, Thoft J, Jacobs E, Mieczkowski T. "Nonmedical management of late luteal phase dysphoric disorder : a preliminary report." The Journal of psychotherapy practice and research, vol. 1, no. 1, 1992, pp. 49-55. |
| Stone AB, Pearlstein TB, Brown WA. "Fluoxetine in the treatment of late luteal phase dysphoric disorder." J. Clin. Psychiatry, vol. 52, no. 7, 1991, pp. 290-3. |
| Stone AB, Pearlstein TB, Brown WA. "Fluoxetine in the treatment of premenstrual syndrome." Psychopharmacology bulletin, vol. 26, no. 3, 1990, pp. 331-5. |
| Pearlstein TB, Frank E, Rivera-Tovar A, Thoft JS, Jacobs E, Mieczkowski TA. "Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder." Journal of affective disorders, vol. 20, no. 2, 1990, pp. 129-34. |
| Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP. "A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor." Archives of General Psychiatry , vol. 46, no. 1, 1989, pp. 45-50. |
Dr. Pearlstein's major research interest has been the assessment and treatment of women with premenstrual dysphoric disorder (PMDD). Seminal studies have included the impact of PMDD on functioning and the efficacy of antidepressant medications and oral contraceptives in PMDD. These studies have included the first placebo-controlled SSRI (fluoxetine) trial in PMDD in the United States (1991), the largest and longest-term naturalistic follow-up study of women with PMDD (1994), a placebo-controlled comparison of fluoxetine and buproprion in PMDD that exhibited the lack of efficacy of nonserotonergic antidepressants in PMDD (1997), a study reporting the benefit of sertraline on psychosocial functioning in a large sample of women with PMDD (2000), and a study confirming the efficacy of an oral contraceptive containing drospirenone for PMDD (2005).
Dr. Pearlstein has also conducted treatment trials in dysthymia, post-traumatic stress disorder, binge eating disorder, and postpartum depression. One of her current research endeavors involves data analyses from a two-site R01 evaluating the treatment efficacy of sertraline, pill placebo, and interpersonal psychotherapy in women with postpartum depression (PI: Caron Zlotnick, PhD and collaborators Michael W. O'Hara and Scott Stuart at Univeristy of Iowa). Another current research project (R34) involves the study of adjunctive integrated chronotherapy for pregnant and postpartum women with depression (PI: Katherine Sharkey, MD, PhD). Dr. Pearlstein is a mentor on Dr. Sharkey’s K23 study examining the role of sleep changes on mood during pregnancy and the postpartum period. Dr. Pearlstein is also a Co-Investigator on a pilot study of the efficacy and potential mechanism of mindfulness based stress reduction in women with irritable bowel syndrome (PI: Ellen Flynn, MD and collaborator Catherine Kerr, PhD).
GRANTS
1. Comparison of Fluoxetine and Placebo in the Treatment of Premenstrual Syndrome, Co-P.I. (Andrea Stone, PI), 1988-90, Eli Lilly.
2. Double-Blind Parallel Comparison of Sertraline, Imipramine and Placebo in Outpatients with Dysthymia, Protocol #R-0211, P.I., 1991-93, Pfizer.
3. Double-Blind Follow-up Study of Sertraline, Imipramine and Placebo in Outpatients with Dysthymia, Protocol #R-0222, P.I., 1992-94, Pfizer.
4. Double-Blind Parallel Comparison of Sertraline and Placebo in Patients with Premenstrual Dysphoric Disorder, Protocol #R-0256, P.I., 1992-94, Pfizer.
5. Comparison of Fluoxetine, Bupropion and Placebo in Late Luteal Phase Dysphoric Disorder, Co-P.I. (Andrea Stone, PI), 1992-95, Eli Lilly.
6. Double-Blind Comparison of Sertraline and Placebo in Outpatients with Post-Traumatic Stress Disorder, Protocol #93CE21-0640, P.I., 1994-96, Pfizer.
7. A Double-Blind Flexible Dose Study Comparing Sertraline and Placebo in Outpatients with Post-Traumatic Stress Disorder, Protocol #95CE21-0671, P.I., 1996-97, Pfizer.
8. A Placebo-Controlled, Double-Blind, Flexible Dose Study of Sertraline in the Treatment of Post-Traumatic Stress Disorder, Protocol #96CE21-0682, P.I., 1997, Pfizer.
9. A 24-Week Open-Label Extension Study of Sertraline in Outpatients with Post-Traumatic Stress Disorder, Protocol #95CE21-0672, P.I., 1996-98, Pfizer.
10. A Double-Blind Continuation Study Comparing Sertraline and Placebo in Outpatients with Post-Traumatic Stress Disorder, Protocol #96CE21-0703, P.I., 1997-98, Pfizer.
11. Double Blind Parallel Comparison of Luteal Phase Dosing with Sertraline and Placebo in Patients with Premenstrual Dysphoric Disorder, Protocol #R-0493, P.I., 1996-99, Pfizer.
12. A Double-Blind Comparison of Fixed Dose Sertraline and Placebo in the Treatment of Premenstrual Syndrome, Protocol #96CE21-0680, P.I., 1997-99, Pfizer.
13. Treatment of Binge Eating Disorder with Fluvoxamine: A Double-Blind, Placebo-Controlled Trial, P.I., 1997-98, Solvay.
14. Combined Dialectical Behavior Therapy and Fluoxetine Treatment of Women with Borderline Personality Disorder, P.I., 1997-98, Executive Council On Research (ECOR) Grant, Department of Psychiatry and Human Behavior, Brown University School of Medicine.
15. A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation Containing Drosperinone 3 mg and Ethinyl Estradiol 30 µg in the Treatment of Premenstrual Syndrome, Protocol #97036, P.I., 1997-99, Berlex.
16. Combined Dialectical Behavior Therapy and Fluoxetine Pharmacotherapy in Patients with Borderline Personality Disorder, P.I., 1997-99, Eli Lilly.
17. Fluoxetine versus Placebo in Posttraumatic Stress Disorder, Protocol #B1Y-MC-HCJL, P.I., 1999, Eli Lilly.
18. Validation of the Calendar of Premenstrual Experiences (COPE), Protocol #99014, P.I., 1999, Berlex.
19. Intermittent Dosing of Fluoxetine in the Treatment of Premenstrual Dysphoric Disorder: Luteal Phase Daily Dosing versus Placebo, Protocol #B1Y-MC-HCJN, P.I., 1998-2000, Eli Lilly.
20. Duloxetine versus Placebo in the Treatment of Major Depression, Protocol #F1J-MC-HMAQ, P.I., 1999-2000, Eli Lilly.
21. A Phase 2 Study of the Use of PH80 for Management of the Symptoms of Clinically Significant Premenstrual Syndrome (PMS), Protocol #PH80 CL015, P.I., 2000-01, Pherin Pharmaceuticals.
22. A Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge Eating Disorder, Protocol #SB237, P.I., 2000-01, Knoll Pharmaceuticals.
23. A Double-Blind, Placebo-Controlled, 3-Arm Fixed Dose Study of Paroxetine CR Continuous Treatment (12.5 mg and 25 mg/day) for Premenstrual Dysphoric Disorder, Protocol #677, P.I., 2000-02, SmithKline Beecham.
24. A 3-Month, Double-Blind, Placebo-Controlled, Fixed Dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients completing Studies 29060/677, 688 or 689, Protocol #711, P.I., 2000-02, SmithKline Beecham.
25. A Double-Blind, Randomized, Placebo-Controlled, 3-Month Clinical Trial of Venlafaxine ER and Sertraline in the Treatment of Posttraumatic Stress Disorder, Protocol #0600B-100735, P.I., 2001-02, Wyeth-Ayerst.
26. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation Containing Drospirenone 3 mg Ethinyl Estradiol 20 µg (as Beta-Cyclodextrin Clathrate) in the Treatment of Premenstrual Dysphoric Disorder (PMDD), Protocol #305141, P.I., 2002, Berlex.
27. A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation Containing Drospirenone 3 mg Ethinyl Estradiol 20 µg (as Beta-Cyclodextrin Clathrate) in the Treatment of Premenstrual Dysphoric Disorder, Protocol #304049, P.I., 2000-03, Berlex.
28. A Comparison of Calcium and Fluoxetine as PMDD Treatments, Co-Principal Investigator (PI: KA Yonkers), 2000-05, Ethel F. Donaghue Women's Health Investigator Program, Yale University School of Medicine.
29. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-Eating Disorder Associated with Obesity, Protocol #CAPSS-220, P.I., 2003-05, Ortho-McNeil.
30. Treating PMS/PMDD: Research versus Clinical Reality. Co-Principal Investigator (PI: KA Yonkers), 9/30/01-8/31/05, NIMH R21 MH062379.
31. Depression Prevention for Poor Pregnant Women. Co-Investigator (PI: C Zlotnick), 6/1/06-4/30/11, NIMH R01 MH071766.
32. Fetal and Neonatal Neurobehavior and Prenatal Antidepressant Exposure. Consultant (PI: A Salisbury), 2/1/08-1/31/13, NIMH R01 MH078033.
33. Group IPT for Major Depression Following Perinatal Loss. Co-Investigator (PI: J Johnson), 6/1/10-2/28/13, NIMH R34 MH086682.
34. Pilot Study of Sleep and Mood in Pregnancy and the Postpartum Period. Co-Principal Ivestigator (PI: K Sharkey), 2010-11, Women and Infants Hospital Center of Excellence Seed Grant.
35. Placebo-Controlled Trial of Sertraline and Interpersonal Psychotherapy for Postpartum Depression. Co-Investigator (PI: C Zlotnick), 9/14/07-5/31/14, NIMH R01 MH074919.
36. Postpartum Depression: Role of Sleep & Genetic Risk in Postpartum Mood Disorders. Mentor (PI: K Sharkey), 12/12/10 -11/30/15, NIMH K23 MH086689.
37. Mindfulness based stress reduction (MBSR) in irritable bowel syndrome (IBS) patients: A pilot study. Co-Investigator (PI: E Flynn), 2013-16, Lifespan.
38. Triple Chronotherapy for Perinatal Depression. Co-Investigator (PI: K Sharkey), 2014-15, The Depressive and Bipolar Disorder Alternative Treatment Foundation.
39. Adjunctive Psychotherapy for Perinatal Bipolar Disorder. Co-Investigator (PI: L Weinstock), 5/7/14-3/31/17, NIMH R34 MH102466.
40. Treatment Decisions for Perinatal Bipolar Disorder. Co-Investigator (PIs: L Weinstock, C Battle), 11/21/14-10/31/17, NIMH R34 MH103570.
41. Integrated Chronotherapy for Perinatal Anxiety. Co-Investigator (PI: K Sharkey), 2014-16, Seleni Institute Research Award.
42. Integrated Chronotherapy for Perinatal Depression. Co-Investigator (PI: K Sharkey), 3/6/15-2/28/18, NIMH R34 MH104377.
| Year | Degree | Institution |
|---|---|---|
| 1982 | MD | New York University |
| 1978 | BA | Wellesley College |
| Resident | Mount Sinai Hospital, psychiatry | 1983-1986 | New York, NY |
| Intern | Mount Sinai Hospital, medicine | 1982-1983 | New York, NY |
| Name | Title |
|---|---|
| Flynn, Ellen | Clinical Associate Professor of Psychiatry and Human Behavior, Clinical Associate Professor of Medicine |
| Sharkey, Katherine | Associate Dean for Gender Equity, Associate Professor of Medicine, Associate Professor of Psychiatry and Human Behavior |
| Zlotnick, Caron | Professor of Obstetrics and Gynecology, Professor of Medicine, Professor of Psychiatry and Human Behavior |
MEMBERSHIP IN SOCIETIES
1983 - 1986 American Medical Association
1986 - 1990 Psychiatric Physicians of Pennsylvania
1987 - 1990 Society of Menstrual Cycle Research
1987 - 1990 American Society for Psychosomatic Obstetrics and Gynecology
1996 - 1998 Secretary, Rhode Island Medical Women's Association
1997 - 2002 American Medical Women's Association
1997 - 2004 North American Menopause Society
2002 - 2004 American Society of Clinical Psychopharmacology
2002 - 2012 Treasurer, Executive Committee, International Association for Women's Mental Health
2003 - 2005 Member-at-Large, Executive Committee, North American Society for Psychosocial Obstetrics and Gynecology
2009 - 2011 President-Elect, North American Society for Psychosocial Obstetrics and Gynecology
2011 - 2013 President, North American Society for Psychosocial Obstetrics and Gynecology
1984 - American Psychiatric Association
1990 - Rhode Island Psychiatric Society
1994 - Rhode Island Medical Women's Association
1996 - North American Society for Psychosocial Obstetrics and Gynecology
1999 - Fellow, American Psychiatric Association
2002 - International Association for Women's Mental Health
2003 - Distinguished Fellow, American Psychiatric Association
2008 - International Society for the Study of Premenstrual Disorders
2012- Rhode Island Medical Society
2012 - Marcé Society for Perinatal Mental Health
2013 - International Society of Psychosomatic Obstetrics and Gynaecology
2013 - Advisory Board, Executive Committee, International Association for Women’s Mental Health
2013 - Postpartum Support International
2014 - North American Menopause Society
2014 - American College of Psychiatrists
| Certification | American Board of Psychiatry and Neurology, Psychiatry | 1988- | |
| Medical License | Rhode Island | 1988-2016 | |
| Medical License | Pennsylvania | 1986-1989 | |
| Medical License | New York | 1983-1987 |
| Director. The Miriam Hospital, 2011-Present |
| Director. Women & Infants Hospital of Rhode Island, 1996-2011 |
| Director. Butler Hospital, 1990-2000 |
| Medical Director. Butler Hospital, 1988-1990 |
| Director. Western Psychiatric Institute and Clinic, 1986-1988 |
Psychiatry Residency
1990 - present PG-3 Seminars Lecturer on Premenstrual Dysphoric Disorder
1990 - present PG-3 Seminars Lecturer on Menopausal Transition
1990 - present PG-3 Seminars Lecturer on Eating Disorders
2007 - present Psychiatry Residency Continuity Clinic Preceptor, one half-day per week
2009 - present Module Leader and Lecturer, Perinatal Psychiatry Curriculum for PG-1/2 and PG-3 residents
2012 - present Elective Director: Women’s Specialty One-Month PG-4 Outpatient Elective (emphasizing reproductive psychiatry)
2014 - present Quality and Safety Course, Faculty and Site Supervisor for PG-3 residents’ year-long quality project
2014 - present Module Leader and Lecturer, Integrated Care Curriculum for PG-4 Psychiatry Residents
Medical School
2007 - present Eating Disorders lecturer, Brain and Behavior Course for 1st year medical students, Alpert Medical School
2015 - present Mentor to 3rd year medical student in the Longitudinal Integrated Clerkship (LIC), Alpert Medical School
